Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology oral vaccine platform. The company is headquartered in South San Francisco, California and currently employs 105 full-time employees. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. The Company’s development programs include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), its first immune-oncology indication. The firm's platform technology employs a vector-based approach and consists of various components, such as vector, antigen, and adjuvant. A vector is a virus used as a carrier to deliver DNA coding for vaccine antigens and an adjuvant selected to activate the immune system. An antigen is a viral or bacterial protein that stimulates an immune response to the targeted pathogen.
Follow-Up Questions
Vaxart Inc의 CEO는 누구입니까?
Mr. Steven Lo은 2024부터 회사에 합류한 Vaxart Inc의 President입니다.
VXRT 주식의 가격 성능은 어떻습니까?
VXRT의 현재 가격은 $0.36이며, 전 거래일에 decreased 0% 하였습니다.
Vaxart Inc의 주요 사업 주제나 업종은 무엇입니까?
Vaxart Inc은 Biotechnology 업종에 속하며, 해당 부문은 Health Care입니다
Vaxart Inc의 시가총액은 얼마입니까?
Vaxart Inc의 현재 시가총액은 $82.4M입니다
Vaxart Inc는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 4명의 분석가가 Vaxart Inc에 대한 분석 평가를 실시했으며, 이는 4명의 강력한 매수, 4명의 매수, 1명의 보유, 0명의 매도, 그리고 4명의 강력한 매도를 포함합니다
